Can a signature molecular-profile define disparate survival in BRAF-positive Gliosarcoma and identify novel targets for therapeutic intervention?
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Cancer Research and Therapeutics"
DOI: 10.4103/jcrt.jcrt_1900_20
Abstract: Purpose: Gliosarcoma (GS) has a low incidence but is aggressively invasive, with poor-survival. Even though GS is recognized as a different subgroup from glioblastoma (GB), there is no molecular panel available to define its clinical… read more here.
Keywords: htert hmga; define; survival; braf ... See more keywords